Cognitive Effects of Atomoxetine in Humans: Genetic Moderators

Completed · Not applicable · Has a placebo group

Conditions studied: Addiction

In brief

The overall goal of this study is to determine if atomoxetine treatment improves selective cognitive functions in abstinent cocaine users, compared to healthy controls. The study will also test if a functional variation of the NET promoter polymorphic region (NETpPR) moderates the cognitive effects of atomoxetine.

Key facts

Study ID

NCT01498549

Run by

Yale University

People needed

35

Starts

2011-12-01

Expected to finish

2013-07-01

Last updated by the study team

2017-07-11

Who can join

Age: 21 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and females, between the ages of 21 and 50;
• No current dependence or abuse of drugs of abuse or alcohol (except and tobacco);
• No current medical problems and normal ECG;
• For women, not pregnant as determined by pregnancy screening nor breast feeding, and using acceptable birth control methods.

You may not qualify if…

• Current major psychiatric illnesses including mood, psychotic, or anxiety disorders;
• History of major medical illnesses; including liver diseases, heart disease, or other medical conditions that the physician investigator deems contraindicated for the subject to be in the study;
• Known allergy to Atomoxetine;
• Use of Monoamine Oxidase inhibitor within the last month (clinically Atomoxetine administration is contraindicated with or within 2 weeks of discontinuation of Monoamine oxidase inhibitor therapy).

Where it is running

• Department of Veterans Affairs — West Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.